Characterizing problematic hypoglycaemia: iterative design and preliminary psychometric validation of the Hypoglycaemia Awareness Questionnaire (HypoA-Q) by Speight, J et al.
Speight, J, Barendse, SM, Singh, H, Little, SA, Inkster, B, Frier, BM, Heller, SR, Rutter, MK and 
Shaw, JA 2016, Characterizing problematic hypoglycaemia: iterative design and preliminary 
psychometric validation of the Hypoglycaemia Awareness Questionnaire (HypoA-Q), Diabetic 
medicine, vol. 33, no. 3, pp. 376-385. 
This is the accepted manuscript. 
©2015, The Authors 
This is the peer reviewed version of the article, which has been published in final form at 
http://dx.doi.org/10.1111/dme.12824. This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Self-Archiving. 
Available from Deakin Research Online: 
http://hdl.handle.net/10536/DRO/DU:30074007 
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/dme.12824 
This article is protected by copyright. All rights reserved. 
Received Date : 01-Jan-2015 
Revised Date   : 10-Apr-2015 
Accepted Date : 01-Jun-2015 
Article type      : Research Article 
 
Short title:Validation of the HypoA-Q  
 
Research:  Complications 
Characterizing problematic hypoglycaemia: iterative design 
and preliminary psychometric validation of the Hypoglycaemia 
Awareness Questionnaire (HypoA-Q) 
J. Speight1,2,3, S. M. Barendse1, H. Singh4, S. A. Little5, B. Inkster6, B. M. Frier6, S. R. 
Heller7, M. K. Rutter8, 9 and J. A. M. Shaw5  
1AHP Research, Hornchurch, UK, 2The Australian Centre for Behavioural Research in Diabetes, Diabetes 
Australia, Victoria, Melbourne, Australia, 3Centre for Mental Health and Wellbeing Research, School of 
Psychology, Deakin University, Burwood, Australia, 4Department of Psychiatry and Neurobehavioral 
Sciences, Division of Behavioral Health and Technology, University of Virginia School of Medicine, 
Charlottesville, USA, 5Institute of Cellular Medicine, Newcastle University, Newcastle, UK, 6Department 
of Diabetes, Royal Infirmary, Edinburgh, UK, 7Academic Unit of Diabetes, Endocrinology & Metabolism, 
University of Sheffield, UK, 8Endocrinology and Diabetes Research Group, Institute of Human 
Development, Faculty of Medical and Human Sciences, University of Manchester, UK and 9Manchester 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic 
Health Science Centre, Manchester, UK  
 
Correspondence to: Jane Speight. E-mail: jane.speight@deakin.edu.au 
 
What's new? 
• Approximately 20–25% of adults with Type 1 diabetes have impaired awareness of hypoglycaemia 
(IAH), which is associated with a six-fold higher risk of severe hypoglycaemia. Existing measures of 
impaired awareness of hypoglycaemia have acknowledged limitations.  
• Comprehensive, collaborative and iterative qualitative work (including adults with Type 1 diabetes 
and clinicians) has generated a new questionnaire designed to characterize IAH and problematical 
hypoglycaemia when awake and asleep, as well as to assess changes over time.  
• Preliminary psychometric validation has shown that the Hypoglycaemia Awareness Questionnaire 
has: good face and content validity; convergent, divergent and known-groups validity; satisfactory 
scale structure and internal consistency reliability; and early indication of predictive validity.  
 
Abstract 
Aims: To design and conduct preliminary validation of a measure of hypoglycaemia awareness and 
problematic hypoglycaemia, the Hypoglycaemia Awareness Questionnaire.  
Methods: Exploratory and cognitive debriefing interviews were conducted with 17 adults (nine of whom 
were women) with Type 1 diabetes (mean ± SD age 48±10 years). Questionnaire items were modified in 
consultation with diabetologists/psychologists. Psychometric validation was undertaken using data from 
120 adults (53 women) with Type 1 diabetes (mean ± SD age 44±16 years; 50% with clinically diagnosed 
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impaired awareness of hypoglycaemia), who completed the following questionnaires: the 
Hypoglycaemia Awareness Questionnaire, the Gold score, the Clarke questionnaire and the Problem 
Areas in Diabetes questionnaire.   
Results: Iterative design resulted in 33 items eliciting answers on awareness of hypoglycaemia when 
awake/asleep and hypoglycaemia frequency, severity and impact (healthcare utilization). Psychometric 
analysis identified three subscales reflecting ‘impaired awareness’, ‘symptom level’ and ‘symptom 
frequency’. Convergent validity was indicated by strong correlations between the impaired awareness 
subscale and existing measures of awareness: (Gold: rs=0.75, P<0.01; Clarke: rs=0.76, P<0.01). Divergent 
validity was indicated by weaker correlations with diabetes-related distress (Problem Areas in Diabetes: 
rs=0.25, P<0.01) and HbA1c (rs=-0.05, non-significant). The impaired awareness subscale and other items 
discriminated between those with impaired and intact awareness (Gold score). The impaired awareness 
subscale and other items contributed significantly to models explaining the occurrence of severe 
hypoglycaemia and hypoglycaemia when asleep. 
Conclusions: This preliminary validation shows the Hypoglycaemia Awareness Questionnaire has robust 
face and content validity; satisfactory structure; internal reliability; convergent, divergent and known 
groups validity. The impaired awareness subscale and other items contribute significantly to models 
explaining recall of severe and nocturnal hypoglycaemia. Prospective validation, including 
determination of a threshold to identify impaired awareness, is now warranted. 
 
Introduction 
Approximately 20–25% of adults with Type 1 diabetes have impaired awareness of hypoglycaemia (IAH) 
[1]; after 25 years almost 50% are affected [2] and the risk of severe hypoglycaemia (SH) is sixfold higher 
[1,3]. IAH may compromise activities such as driving, and glycaemic targets may need to be modified to 
avoid SH [4,5]. While significant impairment can debar affected individuals from driving, neither a 
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definition of IAH nor how it should be assessed are described in the European Union licensing 
regulations [6]. An accurate, reliable and validated method to characterize problematic hypoglycaemia 
(frequency, severity, impact and impaired awareness), is needed to inform compilation of medical 
reports for driving licensing authorities. 
 
Current methods for identifying IAH involve use of the self-report measures the Gold score [3] and the 
Clarke questionnaire [7], separately or in combination [8]. The Gold score is brief (a single question with 
a seven-point response scale) with good face validity but it enables identification only and does not 
facilitate detailed characterization of IAH. The Clarke questionnaire [7] comprises eight questions 
documenting exposure to hypoglycaemia and a subjective estimation of the glycaemic threshold for 
symptom generation. It provides a detailed assessment but has limitations: the SH definition is not that 
of the American Diabetes Association Hypoglycaemia Workgroup [9]; consensus for the glycaemic 
thresholds used is lacking; the recall periods are inconsistent between questions and with the time 
periods used in most clinical trials; and most notably, nocturnal hypoglycaemic events are not captured. 
Although the Gold score and Clarke questionnaire have good concordance in detecting IAH, they share a 
limited ability to characterize or evaluate the severity of IAH and lack some sensitivity to change [8].  
 
Our aim was to design and conduct preliminary psychometric validation of a novel, optimized measure 
for detailed characterization of problematic hypoglycaemia, including frequency, severity, impact and 
onset awareness: the Hypoglycaemia Awareness Questionnaire (HypoA-Q).  
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Patients and methods 
Study 1: design and debriefing of the Hypoglycaemia Awareness Questionnaire 
The design of the HypoA-Q was rigorous and iterative, involving multiple interviews with adults with 
Type 1 diabetes who were experiencing problematic hypoglycaemia. After every two to three 
interviews, diabetologists and psychologists discussed findings, and questionnaire items were refined. 
Interviews continued until an optimized design was achieved (10th draft) with no further concerns being 
raised. Full study details are provided in Appendix S1. 
 
Study 2: psychometric validation of the Hypoglycaemia Awareness Questionnaire 
Procedure 
Adults with Type 1 diabetes were invited to participate during clinic attendance at the Royal Infirmary 
and Western General Hospital, Edinburgh. After providing formal consent, they completed the 
questionnaire booklet (see below). Ethics approval was granted by the West of Scotland Research Ethics 
Committee.  
Participants 
Eligible participants were adults (aged 18–75 years), with established Type 1 diabetes (≥12 months), 
able to read/write in English and who were willing to complete the questionnaires and have clinical data 
extracted from medical records. Half of those approached had been listed on an IAH register after 
clinical assessment by one of the authors (B.M.F.), without application of a scoring system. 
Study measures  
In addition to the newly developed HypoA-Q (described in the Results section), the questionnaire 
booklet included: 
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• Gold score [3]: a score of ≥4 designates IAH.  
• The Guy’s and St Thomas’ Minimally Modified Clarke Hypoglycaemia Survey, derived from the 
Clarke questionnaire [7]: a score of ≥4 designates IAH.  
• Problem Areas in Diabetes (PAID) scale [10]: the total score, derived from this 20-item measure, 
ranges from 0 to 100, with higher scores indicating greater diabetes distress [11].  
 
Statistical analysis 
The scoring on the HypoA-Q was determined using a combination of statistics to yield a profile measure, 
i.e. several item and subscale scores. Exploratory factor analysis was conducted on 17 items (5a–d; 6a–
c; 7–13; 17–19) considered suitable for profiling IAH (including symptoms whether awake or asleep). 
Notably, questions about previous experience of SH were excluded from the impaired awareness 
subscale explorations, on the basis that SH is a consequence of IAH and should not be part of its 
definition. Factor loadings ≥0.3 and ≥0.6 were considered meaningful and high, respectively [12]. To 
support internal consistency reliability, Cronbach’s α of ≥0.70 was considered satisfactory [13]. Sixteen 
items were considered conceptually distinct, relating to reporting of hypoglycaemic events (frequency 
and severity) and related healthcare utilization (items 1, 2a–d), while awake (items 3, 4a–d), and while 
asleep (items 15, 16a–e). These were scored separately and analysed individually providing descriptive 
statistics of frequency, severity and impact of hypoglycaemia. Two open-ended questions (items 14 and 
20) invited qualitative responses. 
 
Statistical analyses were conducted using IBM SPSS for Windows version 21 (Chicago, IL, USA). 
Descriptive statistics are shown as number (percentage) and mean ± SD unless otherwise indicated. All 
statistical tests were conducted using non-parametric statistics because distributions of several 
variables were skewed. Missing data were considered ‘missing completely at random’. 
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Frequency analyses were conducted to examine HypoA-Q completion rates and response ranges. High 
overall completion rates (>95%) were taken as evidence of the questionnaire’s acceptability.  
Convergent validity is an expected strong relationship (i.e. rs≥0.7) between two similar measures. It was 
assessed by correlating the HypoA-Q ‘impaired awareness’ subscale with Gold score and Clarke 
questionaire scores. Divergent validity is an expected weak relationship (i.e. rs<0.3) between two 
dissimilar measures. It was assessed by correlating the HypoA-Q impaired awareness subscale with 
diabetes distress (PAID total score), diabetes duration and HbA1c.  
 
Known-groups validity is the ability of a measure to discriminate between populations when a 
difference is expected. This was assessed by examining differences in HypoA-Q subscale scores 
according to participants’ known hypoglycaemia awareness status (measured with Gold score: <4 vs. ≥4, 
indicating IAH), using the Mann–Whitney test (or a chi-squared test for categorical data).  
 
While predictive validity can only be assessed truly in a prospective study, logistic regression was 
undertaken to examine variables associated with experiencing at least one event (vs. zero events) of SH 
(item 2a; model 1) or hypoglycaemia when asleep (item 15; model 2) in the preceding 6 months. 
Variables with near-significant correlations (P<0.20) were block-entered into the regression models [14]. 
Models were generated to include the Gold score (where P<0.20) and either Clarke score (model A) or 
HypoA-Q (model B), to provide an indication of the extent to which the HypoA-Q may add value over 
existing measures of IAH. It should be noted that questions 3 and 4 on the Clarke questionnaire ask 
about SH in the preceding 6 months and year, respectively, and are included in the Clarke composite 
score, artificially inflating any relationship with self-reported SH. 
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Results 
Study 1: design and debriefing of the Hypoglycaemia Awareness Questionnaire 
The 17 participants [nine women (53%)] were aged 48±10 years, with a mean ± SD Type 1 diabetes 
duration of 28±12 years and HbA1c concentration of 62±11 mmol/mol (7.8±1.0%). All had experienced 
IAH previously but did not necessarily have IAH at time of assessment.  Eight (47%) used multiple daily 
injections and nine (53%) used continuous subcutaneous insulin infusion (insulin pump therapy).  
 
The themes and issues raised by patients, that informed the content of our draft items, are summarized 
using verbatim quotes in Table 1. Further results are provided in Appendix S1. The questionnaire 
(Appendix S2) includes 33 items, plus two free-text items, assessing: 
 
• recall of hypoglycaemia, including mild (self-treated) and severe events (requiring assistance for 
recovery);  
• healthcare utilization related to SH (i.e. paramedic attendance, treatment in casualty 
department or hospital admission); 
• blood glucose thresholds at which symptoms commence and the nature of symptoms 
generated at those thresholds; 
• perceived awareness of symptoms; 
• perceived diminished awareness; 
• frequency of capillary blood glucose monitoring when ‘feeling low’. 
Separate questions enquire about hypoglycaemia while awake and asleep. 
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Study 2: psychometric validation of the Hypoglycaemia Awareness Questionnaire 
Participant characteristics 
Of the 141 clinic attendees approached, 120 (85%) participated, of whom 53 (44%) were women. Their 
mean ± SD age was 44±16 years, Type 1 diabetes duration was 22±13 years and HbA1c concentration 
66±14 mmol/mol (8.2±1.3%). Of the 21 non-participants, 10 agreed but did not return the 
questionnaire, nine gave no reason for non-participation, one had a conflicting appointment and one 
was unable to complete the questionnaire because of SH. Of the 21, nine (43%) were women. Their 
mean ± SD age was 52±11 years and Type 1 diabetes duration 27±15 years. Eleven (52%) had a clinical 
diagnosis of IAH. 
 
Acceptability   
Completion rates were ≥95% for 20 of the 33 items, ≥90% for another 11 and ≥80% for the remaining 
two. One third of participants wrote comments in the free-text boxes (items 14 and 20). Comments 
included details of idiosyncratic symptomatology, typical circumstances surrounding hypoglycaemia 
onset and information to clarify responses to other items. No issues warranted the design of additional 
items. 
 
Scale structure and internal consistency reliability  
Factor loadings and internal consistency reliability are shown in Table 2. Three subscales were 
identified, with total scores for each derived by summating item scores (with higher scores indicating 
greater impairment of awareness):  
• impaired awareness (items 7, 8, 10, 11 and 12);  
• symptom level (items 6a, b and c), reflecting blood glucose thresholds at which autonomic, 
neuroglycopenic and non-specific (malaise)  symptoms of hypoglycaemia [15] are experienced; 
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• symptom frequency (items 5a, b, c and d), detailing symptoms associated with differing levels of 
blood glucose (<2.5; 2.5–2.9; 3.0–3.4; 3.5–3.9 mmol/l). 
Items 9, 13 and 17–19 did not load on these factors and were treated as separate items for scoring 
purposes. The hypoglycaemia while asleep items (17–19) describe a qualitatively different experience 
and the latter two include a ‘not applicable’ response option. 
 
Frequency of hypoglycaemia events and healthcare utilization 
In the preceding week, 73% of participants (86/118) reported having one or more hypoglycaemic event 
(mild or severe, when awake or asleep), with 18% (21/118) reporting three or more events, while 20% 
(23/115) experienced at least one SH event in the preceding 6months. A total of 62 SH events were 
reported by this group (mean ± SD 2.7 ± 3.1 events per person with SH), of which 12 events (19%) 
required paramedic attendance and one resulted in transfer and admission to hospital.   
 
During the preceding 6 months, 94% of participants (111/118) had experienced at least one 
hypoglycaemic event (mild or severe) while awake; 72% (85/118) reported three or more events, and 
33% (39/118) reported experiencing hypoglycaemia at least once a week. A total of 21% (23/109) had 
experienced SH while awake. 
 
During the preceding 6 months, hypoglycaemia while asleep (predominantly nocturnal hypoglycaemia) 
was reported by 64% of participants (75/117). A total of 41% (48/117) had experienced episodes less 
than once a month, while 10% (12/117) reported hypoglycaemia while asleep at least weekly and 28% 
(32/116) had experienced at least one SH event while asleep. Of those, 21 had experienced events 
where they had been given glucose orally, 12 had required glucagon by injection, two had experienced a 
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‘major problem’ (defined as, e.g. a fit, tongue biting, fall, collapse or incontinence). A total of 27 
participants had experienced episodes where they did not wake and only realised afterwards that they 
had experienced a hypoglycaemic event. 
 
Convergent and divergent validity 
Satisfactory convergent validity was demonstrated by highly significant inter-scale correlations between 
the HypoA-Q impaired awareness subscale and both the Gold score (rs=0.70, P<0.01) and the Clarke 
questionnaire (rs=0.76, P<0.01); the Gold and Clarke measures were also strongly correlated (rs=0.70, 
P<0.01). Divergent validity was demonstrated, with impaired awareness being only weakly correlated, 
as expected, with diabetes distress (PAID: rs=0.25, P<0.01) and diabetes duration (rs=0.22, P<0.05), and 
unrelated to HbA1c (rs=-0.04, ns). Lack of correlation between the symptom level/symptom frequency 
subscales and the other measures of IAH (data not reported) suggest that they add a qualitatively 
distinct assessment of IAH.  
 
Known-groups validity 
The impaired awareness subscale discriminated, as expected, between those with and without known 
IAH, according to the Gold score (10.80±3.42 vs 5.09±3.20; P<0.001), although symptom level and 
symptom frequency did not differentiate. Findings were similar when the Clarke questionnaire was used 
to identify IAH (data not shown). As expected, HypoA-Q items that focused on the frequency of SH 
events (items 2a, 4b, 4c) also showed expected differences between those with and without IAH (Table 
3). As expected, items that focused on experience of mild hypoglycaemia did not discriminate between 
those with and without known IAH. 
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Predictive validity 
The HypoA-Q subscales and individual items contributed significantly to a model explaining the 
presence of SH events in the preceding 6 months (Table 4). In model 1A, significant associations with SH 
included sex, Gold score and Clarke questionnaire score, explaining 44% of the variance in SH. When the 
Clarke questionnaire was removed and HypoA-Q included (model 1B), the contribution of the Gold 
score became insignificant; the impaired awareness subscale, being ‘more aware [in the past 6 months] 
of my hypos coming on than I used to be’ (item 13) and ‘others aware first’ of hypoglycaemia while 
asleep (item 18), contributed significantly to a model explaining 61% of the variance in SH.  
 
For associations with hypoglycaemia while asleep, none of the variables included in model 2A 
contributed significantly and the overall model explained 10% of the variance.  Neither Gold score nor 
Clarke questionnaire score were associated with hypoglycaemia while asleep. When the Clarke 
questionnaire was excluded and HypoA-Q included (model 2B), being ‘more aware [in the past 6 
months] of my hypos coming on than I used to be’ (item 13) and reporting ‘symptoms wake me’ (item 
17) contributed significantly to the model, explaining 37% of the variance in hypoglycaemia when 
asleep.  
 
Discussion 
The HypoA-Q fulfils the need for a contemporary, comprehensive assessment of IAH, to improve 
characterization of IAH when awake and asleep. HypoA-Q items also enable systematic characterization 
of frequency and severity of recent hypoglycaemia, including SH-related healthcare utilization.  
A comprehensive, iterative design study generated a detailed profile measure and has shown that the 
questionnaire has good breadth of content, face and content validity. The preliminary psychometric 
validation study showed satisfactory scale structure and internal consistency reliability. Convergent 
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validity was strong: correlations with the Gold score and Clarke questionnaire score were rs≥0.7, 
suggesting that the five-item impaired awareness subscale was a very satisfactory measure of IAH; while 
divergent validity was demonstrated with low correlations between impaired awareness and HbA1c and 
PAID scores. Known-groups validity was also demonstrated. The impaired awareness subscale and 
several SH items distinguished, as expected, between those with impaired and intact awareness 
(according to the Gold score; Table 3). Indeed, the former scored almost two standard deviations higher 
than the latter on the impaired awareness subscale, equivalent to a very large effect size [20]. While it is 
too soon to determine a clinically important cut-off point for impaired awareness, which would require 
longitudinal data and multiple datasets, this sensitivity to between-group differences is certainly 
promising.  
 
The lack of relationships between the symptom level and symptom frequency subscales and other 
variables raises uncertainty about their discriminatory properties and responsiveness; however, it was 
clear in the questionnaire design phase that such subscales added a qualitatively distinct method of 
assessing IAH, which may be useful in routine clinical practice and merits further exploration. 
 
Logistical regression analyses showed that including the HypoA-Q variables in models of severe 
hypoglycaemia and hypoglycaemia while asleep provided greater explanatory power than including the 
Gold score or Clarke questionnaire alone.  The impaired awareness subscale score and item 13 (being 
‘more aware [in the past 6 months] of my hypos coming on than I used to be’) were associated 
significantly with severe hypoglycaemia (Table 4; model 1B), suggesting that they may have predictive 
validity. Item 9 ‘check blood glucose if I feel low’ is likely to be important in the context of those whose 
awareness may not be adequate for driving, although many other behavioural factors determine driving 
risk. While these findings suggest that HypoA-Q is likely to have predictive validity and to be responsive, 
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this needs to be tested fully in a prospective study. The HypoA-Q has been used in the HypoCOMPaSS 
trial [17], with recently documented evidence of its responsiveness to intervention to improve 
awareness of hypoglycaemia [18].  
The HypoA-Q includes items about awareness and hypoglycaemia while asleep, which is not addressed 
by the Gold score or Clarke questionnaire. While the latter were not associated with hypoglycaemia 
while asleep (Table 4; model 2A), item 13 (being ‘more aware [in the past 6 months] of my hypos 
coming on than I used to be’) and item 9 (‘symptoms wake me’) were both associated with 
hypoglycaemia while asleep (Table 4; model 2B). While this information can be gleaned in a clinical 
interview, the use of systematic and comprehensive questioning should be encouraged in clinical and 
research settings, and the HypoA-Q is designed to facilitate this.  
 
Although it takes <7 min to complete, the HypoA-Q was never intended to match the simplicity or 
brevity of the single-item Gold score [3]. Feedback from design study participants indicated they 
considered a single-page questionnaire neither feasible nor desirable. Paradoxically, they found the 
longer questionnaire more acceptable and easier to complete than the initial shorter draft. 
 
A key strength of Study 1 is the rigour with which the questionnaire was designed and debriefed. 
Questionnaire design took account of existing knowledge of problematic hypoglycaemia, IAH syndrome 
and its pathogenesis. It benefited from broad, in-depth consultation, which continued until all issues 
were resolved. Patients with Type 1 diabetes were selected purposefully for their experience of 
hypoglycaemia and IAH, rather than to represent all adults with the condition, but it is important to 
acknowledge that such experience means this was a relatively homogeneous group. A strength of Study 
2 (psychometric validation) is that data were collected in a routine clinical setting, offering opportunity 
to assess HypoA-Q suitability in a broad cross-section of adults with Type 1 diabetes (half with clinically 
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diagnosed IAH), comparing against validated measures of IAH. Despite high response rates, the sample 
size fell slightly short of the ideal (four to five respondents per item) but was more than adequate, 
according to Kline’s criteria of a respondent to item ratio of 2:1 and a minimum of 100 participants [13]. 
Some might regard self-reported hypoglycaemic events rather than objective blinded continuous 
glucose monitoring as a potential limitation of the study; however, the latter does not enable data 
collection over a long period of time in a large number of people or provide a clear assessment of event 
severity without a parallel diary, and is of limited use for diagnosing IAH [16]. Both studies are limited by 
the relative homogeneity of the samples (middle-aged white people with long-standing Type 1 
diabetes). Use of this questionnaire in other populations (e.g. other cultural backgrounds, insulin-
treated Type 2 diabetes) is now required to confirm and expand upon these findings, and prospective 
studies are warranted to demonstrate test–retest reliability, responsiveness and predictive validity.  
 
Overall, the HypoA-Q is likely to enable a more definitive diagnosis of IAH, and comprehensive 
characterization of those with problematic hypoglycaemia who are at high risk of SH and nocturnal 
hypoglycaemic events. This will enable improved classification of the spectrum of hypoglycaemia 
awareness in clinical practice, including evaluation of medical fitness, e.g. for activities such as driving. 
The promising psychometric properties of the HypoA-Q suggest its potential value in clinical trials in 
which IAH is a primary or secondary endpoint.  
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Supporting information 
 
Additional Supporting Information may be found in the online version of this article:  
 
Appendix S1. Design and debriefing of the Hypoglycaemia Awareness Questionnaire. 
Appendix S2. The Hypoglycaemia Awareness Questionnaire.  
 
Table 1 Themes identified during exploratory interviews indicating the need for new questionnaire 
content  
Themes  Participant comments 
Differentiating between 
hypoglycaemia when awake 
and when asleep  
'It’s not necessarily during the day because mine only affect me at night-time' 
(F12) 
'I always have symptoms when it’s low? Well, ‘yes’ during the day, and ‘no’ 
during the night' (M9) 
Awareness as ‘just knowing’ 'I can tell if I’m low without the blood sugar test.  I just can’t tell you how low it 
is' (F6) 
'Sometimes I’ll get a hypo where I have no warning and all of a sudden I’m 
jerking and sometimes I’ll have a hypo where I get to the very early stages and 
I just know I’m going hypo' (F5) 
Idiosyncrasy of symptoms 
(the need to refer to 
symptoms in general) 
'I think sometimes it’s very hard to explain symptoms isn’t it?  You know how 
you feel when you have hypos.  It’s symptoms that you only know yourself 
really' (F6) 
Regaining awareness 'I’m starting to regain some of the symptoms, which, I just couldn’t pick up 
anything before, but now the sweating and that is starting to come back' (F12) 
'I’m more aware than I was.  If you take [me] as I am now, with everything I’m 
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Themes  Participant comments 
taking, with everything I’ve got working for me monitoring-wise, then I’m 
actually better than I used to be' (M9)   
'If you’d gone back before some of the monitoring, hypo awareness was a lot 
less than it is now.  I would have quite low blood sugar before I’d have any 
symptoms at all' (M11) 
Checking blood glucose 
when low 
'I think calling it on autopilot is pretty good because the first thing I think is, ‘I’ll 
check my blood sugar’.  That’s the first thing I tend to think.  Go check it, just 
make sure.  Go check it, stop what you’re doing, because, inevitably, it just gets 
worse.  So, I don’t tend to leave it.  I’ll check it as soon as I can and correct it' 
(M9) 
Differentiating between 
mild and severe events 
'It depends on how severe a hypo.  It’s ... how do you describe, or how do you 
word a question for a mild, severe [hypo]?' (M9) 
Predefined blood glucose 
levels that might be 
personally relevant to 
experience of 
hypoglycaemia 
'I suppose I’ve got kind of, for me I’ve got like three levels of hypo and one is 
kind of, you know… 3.5 upwards, which, to me, really isn’t hypo.  I don’t really 
get any symptoms at all but I would usually eat something or drink something 
at that point because I don’t want to go any lower than that. And then there’s 
the kind of middle one, which I suppose is anything, well maybe even from 
kind of 2.8 up to 3.4, which is my, you know, mild hypo and then there’s, there 
would be the kind of below 2.8, especially when it gets down to close to 2, 
where I would then get the very severe symptoms' (F7) 
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Table 2 Hypoglycaemia Awareness Questionnaire scale structure and internal consistency reliability 
HypoA-Q item  
HypoA-Q subscales factor loadings* 
(principal components)† 
Impaired    
awareness 
Symptom  
level 
Symptom  
frequency 
5a Symptoms experienced at blood glucose readings ‘3.5-3.9 
mmol/l’ 
- - 0.80 
5b Symptoms experienced at blood glucose readings ‘3.0-3.4 
mmol/l’ 
- - 0.92 
5c Symptoms experienced at blood glucose readings ‘2.5-2.9 
mmol/l’ 
- - 0.92 
5d Symptoms experienced at blood glucose readings ‘Less 
than 2.5 mmol/l’ 
- - 0.84 
6a ‘Trembling, shakiness, pounding heart, warmth, sweating, 
hunger’ 
- 0.91 - 
6b ‘Weakness, lack of coordination, confusion, dizziness, 
inability to concentrate, difficulty speaking, blurred vision, 
drowsiness, tiredness, irritability, odd behaviour’ 
- 0.88 - 
6c ‘Nausea, tingling, headache’ - 0.88 - 
7 ‘I have symptoms when my blood glucose is low’  0.66 - - 
8 ‘I ‘just know’ when I’m going hypo by the way I feel’  0.69 - - 
10 ‘Other people recognise I am hypo before I do’ 0.64 - - 
11 ‘I am less aware of my hypos coming on than I used to be’ 0.82 - - 
12 ‘I have lost symptoms I used to have when my blood 
glucose is low’ 
0.84 - - 
Cronbach’s α‡ 0.79 0.86 0.89 
HypoA-Q, Hypoglycaemia Awareness Questionnaire. 
*Factor loadings <0.3 suppressed. 
†Principal component analysis transforms a number of (possibly) correlated variables into a (smaller) number of uncorrelated 
variables called principal components. These components show the internal structure of the data in a way that best explains 
the variance in the data. The factor loadings represent the correlation between the original variables and the factors. 
Suppressing factor loadings <0.3 cleans up the rotated factor matrix and makes it easier to interpret. 
‡Cronbach’s α assesses internal consistency by describing the degree of correlation between various items of the same scale. 
Cronbach’s α has values ranging from 0 to 1. Values between 0.7 and 0.9 indicate good internal consistency and, in general, 
values >0.95 indicate some redundancy among items. 
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Table 3  (a) Known-groups validity: Hypoglycaemia Awareness Questionnaire event frequency, severity and hypoglycaemia awareness scores (continuous 
variables) by known awareness status (Gold score <4 or ≥4) 
HypoA-Q item / subscale 
Gold score 
 
Awareness impaired (≥4) 
n=35 
Awareness partial or intact (<4)
n=81 
Mean (SD) Median (range) Mean (SD) Median (range) Significance 
1 Hypoglycaemia in past week (mild or severe, when awake or asleep) 2.06 (3.58) 1.00 (0–20) 1.59 (1.91) 1.00 (0–11) 1457.5 
2     Hypoglycaemia in past 6 months:      
  2a  Needed help to recover 0.82 (1.53) 0 (0–7) 0.44 (1.86) 0 (0–15) 1594.5** 
 2b  Used emergency services 0.09 (0.29) 0 (0–1) 0.12 (0.60) 0 (0–5) 1320.0 
 2c  Taken to Accident & Emergency (casualty department) 0.00 (0.00) 0 (0) 0.03 (0.16) 0 (0–1) 1237.5 
 2d  Admitted to hospital 0.00  (0.00) 0 (0) 0.01 (0.11) 0 (0 –1) 1254.0 
Impaired awareness subscale (scored 0–20) 10.80 (3.42) 10 (2–18) 5.09 (3.20) 5 (0–14) 2530.5*** 
Symptom level subscale (scored 0–12) 8.03 (2.96) 8 (1–12) 7.30 (3.16) 8 (0–12) 1573.0 
Symptom frequency subscale (scored 0–16) 8.41 (5.00)  8 (0–16) 8.00 (4.52) 8 (0–16) 1327.0 
9 ‘Check blood glucose if feel low’ 3.36 (0.93) 4 (1–4) 3.38 (0.94) 4 (0–4) 1330.0 
13 ‘More aware in past 6 months’ 1.54 (1.04) 2 (0–4) 1.38 (1.05) 1 (0–4) 1504.5 
17 When asleep, ‘symptoms wake me’  2.52 (1.54) 3 (0–4) 1.82 (1.29) 2 (0–4) 941.5* 
18 When asleep, ‘others aware first’ 1.25 (1.35) 1 (0–4) 0.68 (1.12) 0 (0–4) 1247.0* 
HypoA-Q, Hypoglycaemia Awareness Questionnaire. 
Data are the average number of events or the average score per person. * P<0.05, ** P<0.01, *** P<0.001 (Mann–Whitney test) 
Known-groups validity is determined by the degree to which the questionnaire (i.e. HypoA-Q) demonstrates significant expected differences between two groups groups, i.e. people with 
impaired or intact hypoglycaemia awareness (assessed by the Gold score). 
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Table 3b: Known-groups validity: Hypoglycaemia Awareness Questionnaire event frequency, severity and hypoglycaemia awareness scores (categorical 
variables) by known awareness status (Gold score <4 or ≥4) 
HypoA-Q item / subscale 
Gold score 
Significa
nce 
Hypoglycaemia awareness impaired (≥4)   n=35 Hypoglycaemia awareness partial or intact (<4)   n=81 
Never Once or twice 
Three or 
four 
times 
About 
once or 
twice a 
month 
About 
once a 
week 
More 
than 
once a 
week 
Never Once or twice 
Three or 
four 
times 
About 
once or 
twice a 
month 
About 
once a 
week 
More 
than 
once a 
week 
Hypoglycaemia in past 6 months, when awake: 
3 Any hypo when awake 0 (7.6) 10 (28.6) 5 (14.3) 9 (25.7)  6 (17.1) 5 (14.3) 6 (7.6) 16 (24.1) 19 (24.1) 11 (13.9) 16 (20.3) 11 (13.9) 6.54 
4a Had symptoms and able to treat self 2 (6.1) 8 (24.2) 6 (18.2) 7 (21.2) 7 (21.2) 3 (9.1) 6 (7.5) 21 (26.3) 15 (18.8) 12 (15.0) 16 (20.0) 10 (12.5) 0.90 
4b Had symptoms and unable to treat self 18 (56.3) 12 (37.5) 1 (3.1) 1 (3.1) 0 (0) 0 (0) 65 (87.8) 8 (10.8) 1 (1.4) 0 (0) 0 (0) 0 (0) 13.97** 
4c Needed someone else to give sugar by mouth 25.4 (64.5) 10 (32.3) 0 (0) 0(0) 0 (0) 0 (0) 67 (89.3) 6 (8.0) 2 (2.7) 0 (0) 0 (0) 0 (0) 13.44** 
4d Needed someone else to give a glucagon injection 27 (87.1) 4 (3.7) 0 (0) 0 (0) 0 (0) 0 (0) 71 (93.4) 5 (6.6) 0 (0) 0 (0) 0 (0) 0 (0) 1.14 
Hypoglycaemia in past 6 months, when asleep: 
15 Any hypo 15 (44.1) 11 (32.4) 5 (14.7) 2 (5.9) 1 (2.9) 0 (0) 26 (32.9) 34 (43.0) 10 (12.7) 8 (10.1) 1 (1.3) 0 (0) 2.44 
16a Unable to treat self when woke 19 (57.6) 11 (33.3) 1 (3.0) 1 (3.0) 1 (3.0) 0 (0) 61 (77.2) 12 (15.2) 3 (3.8) 2 (2.5) 1 (1.3) 0 (0) 5.45 
16b Someone else gave sugar by mouth 25 (78.1) 6 (18.8) 1 (3.1) 0 (0) 0 (0) 0 (0) 63 (81.8) 11 (14.3) 2 (2.6) 1 (1.3) 0 (0) 0 (0) 0.77 
16c Someone else gave a glucagon injection 29 (90.6) 3 (9.4) 0 (0) 0 (0) 0 (0) 0 (0) 68 (88.3) 6 (7.8) 2 (2.6) 1 (1.3) 0 (0) 0 (0) 1.33 
16d Which led to a major problem, e.g. fit, tongue biting, fall, collapse, incontinence 30 (96.8) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0) 74 (98.7) 1 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0.42 
16e Did not waken and only later realised hypoglycaemia had occurred 24 (75.0) 6 (18.8) 1 (3.1) 1 (3.1) 0 (0) 0 (0) 60 (77.9) 13 (16.9) 2 (2.6) 1 (1.3) 1 (1.3) 0 (0) 0.92 
HypoA-Q, Hypoglycaemia Awareness Questionnaire. 
Data are the number (percentage) in each frequency category. * P<0.05, ** P<0.01, *** P<0.001 (chi-squared test). 
Known-groups validity is determined by the degree to which the questionnaire (i.e. HypoA-Q) demonstrates significant expected differences between two groups, i.e. people with impaired or 
intact hypoglycaemia awareness (assessed by the Gold score). 
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Table 4 Associations with severe hypoglycaemia (Model 1) and hypoglycaemia when asleep (Model 2) 
 
Predictor variables Exp(B) 95% CI P Predictor variables Exp(B) 95% CI P 
Model 1A: SH* (model includes Gold score and Clarke questionnaire) Model 1B: SH* (model includes Gold questionnaire and HypoA-Q) 
Sex 
Age (years) 
Diabetes duration (years) 
Gold  score 
Diabetes distress (PAID) 
Clarke questionnaire score 
Constant 
.20 
1.02 
0.98 
0.48 
1.05 
3.08 
0.12 
0.05, 0.81 
0.96, 1.08 
0.93, 1.04 
0.24, 0.92 
0.99, 1.07 
1.69, 5.60 
<0.05 
ns 
ns 
<0.05 
ns 
<0.001 
ns 
Sex 
Age (years) 
Diabetes duration (years) 
Gold score 
Diabetes distress (PAID) 
‘Impaired awareness’ (HypoA-Q subscale) 
‘Symptom Frequency’ (HypoA-Q subscale) 
‘More aware in past 6 months’ (HypoA-Q item 13) 
‘Symptoms wake me’ (HypoA-Q item 17) 
‘Others aware first’ (HypoA-Q item 18) 
Constant 
0.06 
1.03 
0.96 
.28 
1.04 
2.11 
0.97 
3.39 
0.77 
2.29 
0.00 
0.01, 0.39 
0.96, 1.11 
0.88, 1.06 
0.09, .80 
0.99, 1.10 
1.29, 3.46 
.85, 1.12 
1.23, 9.36 
0.38, 1.58 
1.08, 4.85 
<0.01 
ns 
ns 
ns 
ns 
<0.01 
ns 
<0.05 
ns 
<0.05 
R2  = .44. Model Χ2(6) = 32.70, P<0.001 R2  = .61. Model Χ2(10) = 47.53, P<0.001 
Model 2A: Hypoglycaemia when asleep† (model includes Gold score 
and Clarke questionnaire) 
Model 2B: Hypoglycaemia when asleep† (model includes Gold score and HypoA-Q) 
Age 
Diabetes distress (PAID) 
Clarke questionnaire score 
Constant 
0.98 
1.02 
0.98 
3.37 
0.95, 1.01 
1.00, 1.05 
0.77, 1.24 
ns 
ns 
ns 
 ns  
Age 
Diabetes distress (PAID) 
‘Impaired awareness’ (HypoA-Q subscale) 
‘More aware in past 6 months’ (HypoA-Q item 13) 
‘Symptoms wake me’ (HypoA-Q item 17) 
Constant 
0.98 
1.02 
1.14 
0.58 
2.08 
0.61 
0.95, 1.01 
0.99, 1.06 
1.00, 1.30 
0.35, 0.97 
1.47, 2.93 
ns 
ns 
sn 
<0.05 
<0.001 
ns 
R2  = 0.10. Model Χ2(3) = 8.71, P<0.05 R2  = 0.37. Model Χ2(5) = 34.74, P<0.001 
 
HypoA-Q: Hypoglycaemia Awareness Questionnaire; PAID: Problem Areas In Diabetes scale; SH, severe hypoglycaemia; ns, non-significant. 
 R2 (Nagelkerke) is the percent of variance explained by the model.  
*At least one severe hypoglycaemic event in the past 6 months, assessed using HypoA-Q item 2a; †At least one hypoglycaemic event when asleep, assessed using HypoA-Q item 15. 
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